Genetically proxied blood pressure lowering through calcium channel blockers was associated with cSVD imaging markers, whereas genetically proxied high-density lipoprotein raising through cholesteryl ester transfer protein inhibitors, triglyceride lowering through lipoprotein lipase and weight lowering through gastric inhibitory polypeptide receptor were associated with lower risk of LS. This evidence concerns the gene LPL and Leigh syndrome.